NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team: http ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching May 5, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Maravai Lifesciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ:MRVI) securities during the period from August 7, 2024, through February 24, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On February 25, 2025, before the market ope ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=14 ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1]. Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging Maravai investors who have suffered significant losses to contact them for more information [4]. - The firm has a global reputation for excellence and has recovered billions for victims of fraud and corporate misconduct [4].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. reported disappointing fourth-quarter 2024 earnings, missing analyst expectations and facing a significant price target downgrade due to financial reporting issues and a securities class action lawsuit [1][4][5]. Financial Performance - The company posted an adjusted loss per share of $0.06, which was wider than the expected loss of $0.04, with quarterly revenue at $56.6 million, slightly below the consensus forecast of $56.67 million [2]. - For the full year, Maravai reported revenue of $259 million, consistent with its guidance, but the GAAP net loss widened to $260 million from a $138 million loss in 2023 [3]. Analyst Reactions - Following the disappointing results, Stifel analysts reduced their price target for Maravai by 50%, from $10.00 to $5.00, reflecting concerns over the company's near-term financial outlook and weaker-than-expected revenues and EBITDA [4]. Legal Issues - Maravai is facing a securities class action lawsuit alleging false and misleading statements regarding its financial reporting, particularly concerning revenue recognition and goodwill accounting [5][9]. - The lawsuit claims that the company postponed its fiscal 2024 earnings release, leading to a nearly 22% drop in stock price [5]. Accounting Concerns - CFO Kevin Herde acknowledged errors in revenue recognition, specifically a $3.9 million misrecording due to shipment timing issues, and revealed an $11.9 million non-cash goodwill impairment charge related to the Alphazyme acquisition [6][7]. - These issues highlighted material weaknesses in Maravai's internal controls over financial reporting, which are central to the allegations in the lawsuit [7][9].

RADNOR, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadlin ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024, leading to an overstatement of goodwill [2] - Defendants' positive statements regarding the Company's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=143336&fr ...

Core Insights - Maravai LifeSciences Holdings experienced a significant decline in share price due to revelations of material weaknesses in financial reporting, with a nearly 6% drop on March 19, 2025, following a 21% plunge on February 25, 2025, when the company postponed its earnings release [1][6] Financial Reporting Issues - The company's CFO, Kevin Herde, disclosed an error in revenue recognition that led to $3.9 million being improperly recorded in Q2 2024 instead of Q3, attributed to differing contractual terms that were not communicated to the accounting team [3] - Maravai recorded an $11.9 million non-cash goodwill impairment charge related to its Alphazyme acquisition, indicating that the carrying value exceeded its estimated fair value, which highlighted material weaknesses in internal controls over revenue recognition and goodwill assessments [4] Legal Developments - A securities class action lawsuit has been filed against Maravai, alleging that the company misled investors regarding its internal controls, revenue recognition practices, and goodwill valuation during the class period from August 7, 2024, to February 24, 2025 [2][5] - The lawsuit claims that Maravai overstated revenue and goodwill while failing to disclose systemic weaknesses in its internal controls [5] Market Reaction - Following the announcement of the postponement of the earnings release and the assessment of goodwill impairment and internal controls, analysts downgraded the stock and reduced price targets, leading to a sharp sell-off [6]